Transaction in Own Shares • Dec 5, 2025
Transaction in Own Shares
Open in ViewerOpens in native device viewer
Remedy Entertainment Plc: Remedy has completed the acquisition of the company's own shares
Remedy Entertainment Plc Stock exchange release December 5, 2025, at 7:00 p.m. EET
Remedy Entertainment Plc has completed the acquisitions of the company’s own shares, which were announced on October 31, 2025. During the acquisition period – November 3, 2025 to December 5, 2025 – Remedy repurchased a total of 50,000 own shares, corresponding to approximately 0.37% of the total number of shares. The shares were purchased at an average price of approximately EUR 13.72. The repurchase of the company’s own shares reduced the company’s unrestricted equity by EUR 685,820.55.
After the repurchases, Remedy Entertainment Plc holds a total of 50,000 own shares. The purpose of the repurchases was to acquire shares to optimize Remedy’s capital structure, to otherwise be reassigned, to be held by the company, or to be cancelled. The shares were repurchased otherwise than in proportion to the existing shareholdings of the company’s shareholders in public trading at the market price quoted at the time of purchase. The repurchased shares were acquired based on the authorisations given by the Annual General Meeting on April 10, 2025.
REMEDY ENTERTAINMENT PLC
More information
Aapo Kilpinen
Investor Relations & Business Development Manager
Phone: +358 44 522 0595
Email: [email protected]
Remedy in brief
Remedy Entertainment Plc is a pioneering, globally renowned video game company founded in 1995 and headquartered in Finland with an office in Stockholm, Sweden. Known for its story-driven and visually stunning action games, Remedy has created multiple successful, critically acclaimed franchises such as Control, Alan Wake and Max Payne. Remedy also develops its own Northlight game engine and tools technology that powers many of its games. Remedy’s shares are listed on Nasdaq Helsinki’s main list.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.